Devicare has revamped the websites for their two medical solutions that are unique on the market (first-in-class): Tao-Control® for chronic anticoagulated patients and the Lit-Control® product line for urinary health.
The Catalan Finance Institute (ICF), in collaboration with ACCIÓ (Agency for business competitiveness of the Generalitat of Catalonia), granted Devicare participation loan of 133,000 euros as part of the Corporate Entrepreneurship Programme in order to join...
The Association of Out-Patient Clinics and Entities of the Community of Madrid (ACESIMA) and Devicare have signed a strategic collaboration agreement to promote R&D&I and the use and training of innovative healthcare services and technologies intended for the in-home self-management of chronic patients in therapeutic fields such as the cardiovascular and urological fields, among others.
The Laboratory of Renal Lithiasis Research at the University of the Balearic Islands (UIB) will carry out a study among patients to evaluate the effects of theobromine, a substance that acts as an inhibitor of uric acid crystallisation in urine and that was patented as a dietary supplement by the UIB research team led by Dr. Fèlix Grases. The study will be carried out in collaboration with the Urology Service of the Hospital de Manacor,...
Devicare has joined the Associate Collaborators' Forum (FAC) of The Catalan Hospitals Union (La Unió), a body made up of more than 25 industrial and service companies that operate in the health, social and attention to dependency fields. Through this forum, La Unió aims to promote the relationship between the associate collaborators, such as Devicare, and the health and social centers of Catalonia in order to encourage partnerships for innovation in management and also strengthen the role of business lobbying in the sector.
Devicare has signed an agreement with the company Inmave to market the family of Lit-Control® products in Colombia for the domiciliary control of frequent urological pathologies. Colombia is the second American country and the fourth globally, after Spain, Mexico and France, to distribute this first-in-class method. The two companies have begun the regulation process with the Colombian National Institute for Medicine and Food Surveillance (INVIMA) with the support of ACCIÓ de Bogotá's office.
Devicare has signed a collaboration agreement with the Allegra Residential Complex in Sabadell, Barcelona in order to offer Lit-Control® and Tao-Control® to its residents. These two innovative services will allow users of the nursing home (161 beds), rental apartments (27 beds) and the day centre who suffer from long-term urological diseases, such as recurrent urinary tract infections, or who take oral anticoagulants, to self-monitor their health with the benefits that this entails.
Devicare se prepara para introducir en Francia la familia de productos Lit-Control® (dispositivo médico y suplementos alimenticios) y así potenciar el autocontrol domiciliario de patologías urológicas frecuentes a través del manejo y el control del pH urinario. Con este fin, la compañía acaba de incorporar al Dr. François Schutze como Country Manager. El Dr. François…
Devicare, a company specializing in innovative medical devices for chronic home care patients under Remote Patient Monitoring (RPM), has closed out a seed round of 3 million euros. This funding will be used to consolidate the launch of clinical studies of two of Devicare's main product lines on the Spanish market: Lit-Control® for prevention and self-management of recurring urinary diseases and Tao-Control® for self-management of patients who take oral anticoagulants (Sintrom®, Aldocumar®, etc.).
The National Innovation Company (ENISA) has granted Devicare a loan of EUR 270,000 in order to support its expansion plan. This amount is allocated from the ENISA Entrepreneurs line of credit, which finances innovative SMEs so that they can invest in and develop their projects. The maximum loan amount granted is EUR 300,000. This year the company expects to obtain sales of 1.1 million euros and introduce the Lit-Control® line on new international markets, as well as consolidate the Tao-Control® service in Spain. The Devicare staff currently consists of 20 professionals. This is not the first time Devicare has received support from ENISA.
Board Member and Private Investor in different biotech start-ups.
Former President of Medical Devices Committee at Catalonia Association of Biotech Companies.
Master in Business Administration.
Master in International Business.
Master in Entrepreneurship & Innovation.
BSc. Industrial Engineering.
BSc. Electronic Engineering.
+10 years of experience in Business Development in MD companies.
QMS Manager at Mesoestetic.
Deputy Quality Manager at SANJO.
PDD at IESE.
Master in Business Administration.
BSc in Chemical Engineering.
+15 years of experience managing QA and QC in different industrial companies (pharma and automotive sectors)
Marketing Director at Rubió.
Marketing Director at Lacer.
Master in Business Administration.
BSc in Law.
+25 years in strategic marketing positions managing budgets +€20 M, sales force +300 representatives, and having launched +10 products to the market in Urology and Cardiology.
+15 Years of experience in strategic positions regarding prototype and production in prestigious companies as Sanyo or Ateknea. Master’s in production management. BSc Electronic Engineering.
Scientific Director at AB-Biotics
PhD in Microbiology
BSc in Food Science and Technology
BSc in Biology
+15 years of experience in strategic research positions managing the development of innovative nutraceuticals and monitoring clinical trials
Financial Director at Medichem.
Financial Director at Combino.
Master in Financial Management.
BSc in Business Administration.
+20 years of experience in strategic financial positions managing budgets of +€80 M, investments of +€50 M and being in charge of the M&A of Combino by Medichem Group.
System Manager at Ficosa.
R&D Manager at FTE Maximal.
R&D Manager at SANYO.
Master in Project Management.
BSc in Telecom. Engineering.
+20 years of experience in strategic R&D positions managing the development of successful products and creating R&D teams from scratch to +120 people.